ClinicalTrials.gg
Drug

Daclatasvir clinical trials

Also written BMS-790052, Daklinza, GS-7977 and DCV.

studies test it
100
open now
1
in phase 3
36
first study started
2007

How each study uses daclatasvir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the daclatasvir studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
24 Jul 2015 · DAKLINZA · NDA 206843 (FDA, Drugs@FDA)
European Union
22 Aug 2014 · Daklinza · EMEA/H/C/003768 (EMA; now expired)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Daclatasvir
47
Daclatasvir (DCV)
3
Daclatasvir 60 mg
2
SOF+DCV
2
Sovaldi®
2

Brand

Daklinza
10

Development codes

BMS-790052
33
GS-7977
2
PSI-7977
2
BMS-790052-05
1

Other names

DCV
2

In one entry with another drug

Given together, or one or the other

sofosbuvir and daclatasvir
5
Sofosbuvir/Daclatasvir
4
DCV/ASV/BMS-791325
4
DCV 3DAA FDC
2

Studies by the year they started

100 studies that test it; most in 2014 (18)

Studies that test daclatasvir, by start year
YearStudies
20071
20081
20097
20104
20116
20129
20138
201418
201518
201610
20175
20183
20191
20203
20211
20222
20232
20261

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
19
Phase 2
40
Phase 3
36
Phase 4
7
No phase
5

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 62 · Other 38

Bristol-Myers Squibb (50) · Humanity and Health Research Centre (6) · ANRS, Emerging Infectious Diseases (3) · Tehran University of Medical Sciences (3) · Assiut University (3) · Genuine Research Center, Egypt (3) · Janssen Research & Development, LLC (2) · Tanta University (2)

Often tested with

Tested in the same studies.

Sofosbuvir (29) · Asunaprevir (25) · Ribavirin (13) · Simeprevir (11) · Beclabuvir (9) · Peginterferon lambda-1a (5) · Ledipasvir, sofosbuvir drug combination (4) · Ritonavir (4)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 1, 1 in phase 3

Studies that test daclatasvir, phase 3 first.

Studies

Open first, then newest update. How each study uses daclatasvir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 100

See all 100 studies that test daclatasvir →

Given beside what is tested · 17 — daclatasvir is usual care or a partner of the new treatment
As the comparator · 3 — what is tested is compared with daclatasvir

What changed recently

From the registry's own updates since Oct 20, 2026.

Codes

What other systems call daclatasvir · ClinicalTrials.gg INT005615

  • MeSH (NLM) C549273daclatasvirConfirmed NLM, Wikidata
  • UNII (FDA) LI2427F9CIDACLATASVIRConfirmed FDA, NLM, Wikidata
  • RxNorm 1606218Confirmed FDA, Wikidata
  • Wikidata Q5207712daclatasvirConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C114981DaclatasvirOne source FDA
  • DrugBank DB09102One source Wikidata

Also registered as daclatasvir hydrochloride (UNII 50ZO25C11D · RxNorm 1606217).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.